Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
ACC.25 – In STRIDE, the GLP-1RA semaglutide reduced maximal walking distance, symptoms and QoL in patients with PAD and T2D compared with placebo. “This represents a new therapeutic option for patients with PAD and T2D,” says Marc Bonaca.
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Deepak Bhatt, MD
